FR14C0042I1 - Implant injectable a liberation prolongee comprenant un noyau a matrice bioerodable et un revetement bioerodable - Google Patents

Implant injectable a liberation prolongee comprenant un noyau a matrice bioerodable et un revetement bioerodable

Info

Publication number
FR14C0042I1
FR14C0042I1 FR14C0042C FR14C0042C FR14C0042I1 FR 14C0042 I1 FR14C0042 I1 FR 14C0042I1 FR 14C0042 C FR14C0042 C FR 14C0042C FR 14C0042 C FR14C0042 C FR 14C0042C FR 14C0042 I1 FR14C0042 I1 FR 14C0042I1
Authority
FR
France
Prior art keywords
drug
core
bioerodable
skin
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR14C0042C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eyepoint Pharmaceuticals Inc
Eyepoint Pharmaceuticals US Inc
Original Assignee
Psivida US Inc
Psivida Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/714,549 external-priority patent/US8871241B2/en
Application filed by Psivida US Inc, Psivida Inc filed Critical Psivida US Inc
Publication of FR14C0042I1 publication Critical patent/FR14C0042I1/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Prostheses (AREA)
FR14C0042C 2003-11-13 2014-05-20 Implant injectable a liberation prolongee comprenant un noyau a matrice bioerodable et un revetement bioerodable Active FR14C0042I1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/714,549 US8871241B2 (en) 2002-05-07 2003-11-13 Injectable sustained release delivery devices
US54336804P 2004-02-09 2004-02-09
EP04796413A EP1696822B1 (en) 2003-11-13 2004-10-26 Injectable sustained release implant having a bioerodible matrix core and a bioerodible skin

Publications (1)

Publication Number Publication Date
FR14C0042I1 true FR14C0042I1 (fr) 2014-06-27

Family

ID=34636703

Family Applications (1)

Application Number Title Priority Date Filing Date
FR14C0042C Active FR14C0042I1 (fr) 2003-11-13 2014-05-20 Implant injectable a liberation prolongee comprenant un noyau a matrice bioerodable et un revetement bioerodable

Country Status (20)

Country Link
EP (2) EP1696822B1 (es)
JP (3) JP5661226B2 (es)
AT (1) ATE460901T1 (es)
AU (1) AU2004292957C1 (es)
CA (1) CA2545650C (es)
CY (1) CY1114947T1 (es)
DE (1) DE602004026106D1 (es)
DK (1) DK1696822T3 (es)
ES (2) ES2340389T3 (es)
FR (1) FR14C0042I1 (es)
HK (1) HK1148931A1 (es)
IL (1) IL175584A (es)
MX (1) MXPA06005431A (es)
NO (1) NO20062362L (es)
NZ (3) NZ575950A (es)
PL (2) PL2233112T6 (es)
PT (2) PT1696822E (es)
SI (1) SI1696822T1 (es)
TW (2) TWI496597B (es)
WO (1) WO2005051234A2 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6375972B1 (en) 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
ATE460901T1 (de) 2003-11-13 2010-04-15 Psivida Inc Injizierbares implantat mit verzögerter freisetzung mit einem bioerodierbaren matrixkern und einer bioerodierbaren haut
JP2008504938A (ja) 2004-07-02 2008-02-21 レイザー，エリオット 治療媒体送出装置およびその送出装置を用いて治療媒体を眼に送り出す方法
US20070149593A1 (en) * 2005-12-23 2007-06-28 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
NZ595623A (en) 2006-03-31 2013-01-25 Mati Therapeutics Inc A drug insert surrounded by a sheath to expose a polymer containing a drug to surrounding tissues or an eye
UA97971C2 (ru) 2007-06-08 2012-04-10 Берингер Ингельхайм Интернациональ Гмбх Препарат невирапина пролонгированного высвобождения
JP5411140B2 (ja) 2007-09-07 2014-02-12 キュー エル ティー インク． 涙管インプラントの検出
FR2927798B1 (fr) * 2008-02-25 2011-03-04 C L Investissements Procede de fabrication d'un dispositif contraceptif intra-uterin et installation pour la mise en oeuvre de ce procede
US20100278895A1 (en) 2009-04-30 2010-11-04 Medtronic, Inc. Antioxidants and antimicrobial accessories including antioxidants
JP2013515741A (ja) * 2009-12-23 2013-05-09 サイヴィーダ ユーエス，インコーポレイテッド 持続放出性送達デバイス
EP2555749B1 (en) * 2010-04-06 2016-10-26 Allergan, Inc. Sustained-release reservoir implants for intracameral drug delivery
AU2011256259A1 (en) 2010-05-17 2012-11-08 Novaer Holdings, Inc. Drug delivery devices for delivery of ocular therapeutic agents
US8911427B2 (en) 2010-12-28 2014-12-16 Medtronic, Inc. Therapeutic agent reservoir delivery system
CN103402582A (zh) * 2011-02-11 2013-11-20 普西维达公司 使用抗水肿疗法治疗黄斑水肿的方法
EP3290024B1 (en) 2011-08-29 2019-04-17 Mati Therapeutics Inc. Sustained release delivery of active agents to treat glaucoma and ocular hypertension
US9974685B2 (en) 2011-08-29 2018-05-22 Mati Therapeutics Drug delivery system and methods of treating open angle glaucoma and ocular hypertension
EP2750666B1 (en) 2011-08-30 2017-10-04 Universiteit Gent Multi-layered release formulation
CA2866330A1 (en) * 2012-05-30 2013-12-05 Boston Scientific Scimed, Inc. Injectable biodegradable particles for controlled therapeutic agent release
CA2969171C (en) 2014-12-18 2023-12-12 Dsm Ip Assets B.V. Drug delivery system for delivery of acid sensitive drugs
WO2018231811A1 (en) * 2017-06-13 2018-12-20 EyePoint Pharmaceuticals, Inc. Bioerodible drug delivery devices
FR3085841B1 (fr) * 2018-09-14 2020-12-04 Oreal Procede de preparation de capsules et systeme associe
EP3698841A1 (en) * 2019-02-19 2020-08-26 L'oreal Injection device
JP2023517987A (ja) * 2020-03-17 2023-04-27 アーロン エイチ． ブレイジー， 延長された薬物放出のための膨張可能なマルチ賦形剤の構造化された剤形

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3630200A (en) * 1969-06-09 1971-12-28 Alza Corp Ocular insert
US4014335A (en) * 1975-04-21 1977-03-29 Alza Corporation Ocular drug delivery device
US5091185A (en) * 1990-06-20 1992-02-25 Monsanto Company Coated veterinary implants
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US5443505A (en) * 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US6051576A (en) 1994-01-28 2000-04-18 University Of Kentucky Research Foundation Means to achieve sustained release of synergistic drugs by conjugation
US5550050A (en) * 1994-04-15 1996-08-27 Cytotherapeutics, Inc. Method for implanting encapsulated cells in a host
US5486328A (en) 1994-05-31 1996-01-23 Randcastle Extrusion Systems, Inc. Extrusion surge suppressor and method
US5518672A (en) 1994-05-31 1996-05-21 Randcastle Extrusion Systems, Inc. Extrusion surge controller and method
US5569429A (en) 1995-05-05 1996-10-29 Randcastle Extrusion Systems, Inc. Dynamic seal and sealing method
US5773019A (en) * 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US5902598A (en) * 1997-08-28 1999-05-11 Control Delivery Systems, Inc. Sustained release drug delivery devices
US6476079B1 (en) * 1999-12-23 2002-11-05 Leiras Oy Devices for the delivery of drugs having antiprogestinic properties
US6375972B1 (en) * 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
SE0001893D0 (sv) * 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab Medical arrangement
JP2004535431A (ja) * 2001-06-22 2004-11-25 サザン バイオシステムズ， インコーポレイテッド ゼロ次長期放出同軸インプラント
AUPR602401A0 (en) * 2001-06-29 2001-07-26 Smart Drug Systems Inc Sustained release delivery system
AUPR951501A0 (en) * 2001-12-14 2002-01-24 Smart Drug Systems Inc Modified sustained release pharmaceutical system
AU2002351739A1 (en) * 2001-12-18 2003-06-30 Novo Nordisk A/S Solid dose micro implant
ATE460901T1 (de) 2003-11-13 2010-04-15 Psivida Inc Injizierbares implantat mit verzögerter freisetzung mit einem bioerodierbaren matrixkern und einer bioerodierbaren haut

Also Published As

Publication number Publication date
PL1696822T3 (pl) 2010-08-31
DE602004026106D1 (de) 2010-04-29
NO20062362L (no) 2006-08-13
SI1696822T1 (sl) 2010-07-30
AU2004292957C1 (en) 2011-04-28
NZ575950A (en) 2010-06-25
PL2233112T6 (pl) 2014-11-28
PT1696822E (pt) 2010-04-28
TW200526285A (en) 2005-08-16
WO2005051234A2 (en) 2005-06-09
TW201422269A (zh) 2014-06-16
ES2447816T7 (es) 2014-06-25
EP2233112A3 (en) 2011-03-02
JP2014040479A (ja) 2014-03-06
NZ581461A (en) 2011-04-29
NZ547619A (en) 2009-06-26
AU2004292957B2 (en) 2010-09-09
EP1696822B1 (en) 2010-03-17
MXPA06005431A (es) 2007-01-25
IL175584A0 (en) 2006-09-05
CA2545650C (en) 2015-08-18
JP2012072180A (ja) 2012-04-12
ES2340389T3 (es) 2010-06-02
ATE460901T1 (de) 2010-04-15
PL2233112T3 (pl) 2014-05-30
JP5918195B2 (ja) 2016-05-18
EP2233112B1 (en) 2013-11-20
EP2233112B3 (en) 2014-05-14
WO2005051234A3 (en) 2005-11-10
EP1696822A2 (en) 2006-09-06
TWI445559B (zh) 2014-07-21
CA2545650A1 (en) 2005-06-09
JP5661226B2 (ja) 2015-01-28
DK1696822T3 (da) 2010-05-17
ES2447816T3 (es) 2014-03-13
EP2233112A2 (en) 2010-09-29
PT2233112E (pt) 2014-02-27
AU2004292957A1 (en) 2005-06-09
IL175584A (en) 2015-05-31
TWI496597B (zh) 2015-08-21
JP2007512248A (ja) 2007-05-17
JP5526114B2 (ja) 2014-06-18
HK1148931A1 (en) 2011-09-23
CY1114947T1 (el) 2016-12-14

Similar Documents

Publication Publication Date Title
FR14C0042I1 (fr) Implant injectable a liberation prolongee comprenant un noyau a matrice bioerodable et un revetement bioerodable
Teoh et al. Fabricating scalable, personalized wound dressings with customizable drug loadings via 3D printing
DE69929055T2 (de) Verfahren zur spritzgussherstellung von vorrichtungen mit kontrollierter wirkstofffreisetzung und damit hergestellte vorrichtung
AU651084B2 (en) Article for the controlled delivery of an active substance, comprising a hollow space fully enclosed by a wall and filled in full or in part with one or more active substances
WO2011012137A3 (en) A medical device of polyolefin
Johnson et al. Drug eluting implants in pharmaceutical development and clinical practice
WO2007041410A3 (en) Sustained release small molecule drug formulation
BRPI0410956A (pt) pelìculas com base em óxido de polietileno e sistemas de liberação de droga feitos delas
ES2093625T3 (es) Administracion extendida de farmaco de moleculas pequeñas solubles en agua.
Masood Application of fused deposition modelling in controlled drug delivery devices
CA2484632A1 (en) Processes for forming a drug delivery device
DE50103340D1 (de) Verfahren zur herstellung aktivstoffhaltiger kapseln mit ultradünner wandschicht
DE60022332D1 (de) Ketoprofen mikrogranulat, verfahren zur herstellung desselben sowie pharmazeutische zusammensetzungen
Bagheri et al. 3D Printing of Customized Drug Delivery Systems with Controlled Architecture via Reversible Addition‐Fragmentation Chain Transfer Polymerization
Alkhalaf et al. Review of polydimethylsiloxane (pdms) as a material for additive manufacturing
PT1638534E (pt) Uso de etanol como plastificante para preparar implantes subcutâneos contendo princípios activos termolabiais dispersados numa matriz plga
IN2012DN04939A (es)
EP2558271A1 (de) Kanülenvorrichtung und verfahren und vorrichtung zum bestücken einer kanülenvorrichtung mit einem implantat
CY1114534T1 (el) Συσκευες ενεσιμης χορηγησης με παρατεταμενη αποδεσμευση
EP2072216A3 (en) Manufacturing method and apparatus of optical goods
US20240277907A1 (en) Compositions of extended release coatings and methods for applying extended release coatings
Bar-Shalom et al. Extrudable Technologies for Controlling Drug Release and Absorption
MY135804A (en) Processes of forming a drug delivery device
TW200500094A (en) Sustained release dosage forms of anesthetics for pain management